SPP1 and ovarian carcinoma: Bandopadhyay et al. have reviewed that the expression of OPN is attenuated by HMGR (3-hydroxy-3-methylglutaryl CoA reductase) inhibitor in ovarian cancer, whereas parecoxib, a COX-2 inhibitor suppresses the OPN expression via NR4A2/Wnt pathway thereby reducing the tumor growth in colorectal cancer [11].